Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.

Clinical Trial Description

This is a multicenter, multicohort, open label, single-arm, Phase 2 study to assess the efficacy and safety of tabelecleucel for the treatment of EBV-associated diseases in participants who are newly diagnosed or relapsed/refractory to prior treatment. Newly diagnosed or relapsed/refractory participants will be enrolled in one of the following cohorts: - EBV+ lymphoproliferative disease (LPD) in the setting of primary immunodeficiency (PID) (PID LPD) - EBV+ LPD in the setting of acquired (non-congenital) immunodeficiency (AID) (AID LPD) - EBV+ posttransplant lymphoproliferative disorder involving the central nervous system (CNS PTLD) - EBV+ PTLD where standard first line therapy (rituximab or chemotherapy) is not appropriate, including CD20 negative disease - EBV+ sarcomas, including leiomyosarcoma (LMS) - Chronic active EBV (CAEBV) and EBV+ hemophagocytic lymphohistiocytosis (HLH) (CAEBV/HLH cohort) Tabelecleucel will be administered in cycles lasting for 35 days. During each cycle, participants will receive tabelecleucel at a dose of 2 x 10^6 cells/kg intravenously (IV) weekly for 3 weeks, followed by observation through Day 35. Treatment will continue until maximal disease progression, unacceptable toxicity, or initiation of nonprotocol therapy for the underlying disease. For EBV+ sarcoma cohort, treatment will continue until disease progression, unacceptable toxicity, or up to 24 months from first dose. Participants who fail to respond to initial tabelecleucel treatment may continue tabelecleucel with a different human leukocyte antigen (HLA) restriction (termed a Restriction Switch), if available; administration of tabelecleucel with up to 4 different HLA restrictions is allowed for any participant. Participants will complete a safety follow-up visit at 30 days after the last dose. Participants without documented disease progression will be assessed every 3 months after the safety follow-up visit for continued evaluation of disease response until the end of study (EOS) visit at 24-month after first dose. Participants with disease progression any time prior to the EOS visit will continue to be followed every 3 months for survival status until the EOS visit. An adaptive 2-stage design will be used for each cohort in this study. For each cohort, approximately 8 participants will be enrolled in Stage 1. The decision to move to Stage 2 enrollment will be based on an interim analysis of the first 8 evaluable participants in the cohort using investigator's assessment (per defined radiologic, clinical, and/or laboratory response criteria). The number of participants enrolled in Stage 2 for each cohort will depend on the number of observed responders in Stage 1. ;

Study Design

Related Conditions & MeSH terms

  • Allogeneic Hematopoietic Cell Transplant
  • Chronic Active Epstein-Barr Virus (CAEBV)
  • Chronic Active Epstein-Barr Virus With Hemophagocytic Lymphohistiocytosis (HLH)
  • EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (AID LPD)
  • EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (PID LPD)
  • EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
  • EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (CNS PTLD)
  • EBV+ Sarcomas
  • Epstein-Barr Virus (EBV)-Associated Diseases
  • Epstein-Barr Virus Infections
  • Immunologic Deficiency Syndromes
  • Leiomyosarcoma
  • Lymphohistiocytosis, Hemophagocytic
  • Lymphoproliferative Disorders
  • Primary Immunodeficiency Diseases
  • Solid Organ Transplant Complications
  • Stem Cell Transplant Complications
  • Virus Diseases

NCT number NCT04554914
Study type Interventional
Source Atara Biotherapeutics
Contact Study Director
Phone 650-278-8930
Status Recruiting
Phase Phase 2
Start date July 14, 2021
Completion date May 2029

See also
  Status Clinical Trial Phase
Completed NCT03482154 - Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
Completed NCT03042676 - Electronic Database for the Follow up of the ATG_FamilyStudy
Recruiting NCT03871296 - DNA Methylation in Allogeneic Hematopoietic Stem Cell Transplantation.
Recruiting NCT04502628 - Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT N/A
Completed NCT05352789 - Nutrition and Metabolic Prehabilitation in HSCT Patients UK and ROI. BSBMT Multi-centre Survey.
Recruiting NCT03793517 - Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT Phase 2/Phase 3
Completed NCT03454568 - The Patients' Experience After Stem Cell Transplant
Recruiting NCT05466201 - The Use of Eltrombopag Post HSCT in BMFS Phase 2/Phase 3
Not yet recruiting NCT04080622 - Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation. Phase 3
Recruiting NCT05523336 - Pro-ADM vs PCT in Patients With Complications Post Hematopoietic Stem Cell Transplantation
Completed NCT03355235 - Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant
Completed NCT04888286 - DSAs in Patients Undergoing Allo-HSCT From Mismatched Donors
Active, not recruiting NCT03967665 - Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution Phase 3
Not yet recruiting NCT05104268 - Study of a New Medical Device for Oral Mucositis Phase 1/Phase 2
Recruiting NCT04623424 - Intestinal Microbiota in Stem Cell Transplant Transplant Admission
Active, not recruiting NCT04669210 - PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT Phase 2
Completed NCT03489551 - Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients Phase 4
Completed NCT04106089 - Sleep in Pediatric HSCT N/A
Not yet recruiting NCT05421416 - Loratadine for the Prevention of G-CSF-related Bone Pain Phase 2
Not yet recruiting NCT05590091 - Study on Intelligent Nutrition Support Therapy for Hematopoietic Stem Cell Transplantation Recipients N/A